Novartis First Company Accredited with Global 'CEO Cancer Gold Standard'
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organisation CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company's efforts to provide support to Novartis associates in the prevention, diagnosis and treatment of cancer.
"At Novartis, we believe that everyone should have access to early screening programmes and innovative therapies," said Joseph Jimenez, CEO of Novartis. "Our efforts for our associates, which are recognised by this designation, are an extension of our goal to redefine cancer for all patients."
Novartis is passionate about the discovery and development of innovative medicines to help provide a broad range of new therapies and practical solutions to advance care of patients. The company's research is driven by a distinctive scientific and clinical strategy focusing on unmet medical needs and knowledge of disease pathways. The Novartis research strategy leverages biomarkers and targeted drug development focused on individual patients. The company's extensive portfolio of access-to-treatment projects adapts to patients' needs, products, collaborators and countries.
Novartis first achieved CEO Cancer Gold Standard designation in the US, and quickly extended these resources around the world. Since then, the company has offered programs such as
• adding preventive health services in Portugal
• a yearlong plan on health promotion and its benefits in the Philippines
• regular screenings for colon and breast cancers in Japan and Brazil.
The impact has been significant. In fact, through the Novartis cancer screening programme alone, the company has already documented cases of early cancer detection among our associates and has been able to offer the kind of support and treatment that helps to change lives. Novartis continues to expand the programme to leverage the company's internal expertise and expand our cancer network and resources to support employees and their families with the best medical, emotional and physical support possible.
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance